In in vitro and in vivo models of multiple myeloma and non-Hodgkin’s lymphoma, including anaplastic large cell lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma, CFT7455 demonstrated higher binding affinity to CRBN E3 ligase complex and greater activity than other investigational and approved agents in similar classes [208,209]. This evidence concerns the gene CRBN and diffuse large B-cell lymphoma.